TEV-408 Phase 2b Bet: Promising IL-15 Signal, But Durability and Comparator Gaps Threaten Approval Odds

Teva Advances Anti-IL-15 Antibody TEV-’408 to Phase 2b for Vitiligo

Teva Pharmaceutical Industries Ltd. announced its decision to advance TEV-’408, an investigational anti-interleukin-15 monoclonal antibody, into a Phase 2b study for vitiligo in Q4 2026. This follows encouraging results from an ongoing Phase 1b open-label study in adults with active or stable non-segmental vitiligo, which demonstrated improvements in skin pigmentation and a favorable safety profile. Nearly 75% of patients reported improvement in facial vitiligo, with 42% achieving F-VASI50 and 21% achieving F-VASI75 at week 24. The drug is designed for convenient quarterly subcutaneous dosing.

• The ongoing Phase 1b study of TEV-’408 showed significant improvements in skin pigmentation for patients with active or stable non-segmental vitiligo. At week 24, nearly 75% of evaluable participants experienced improvement in facial vitiligo, with 42% achieving F-VASI50 and 21% achieving F-VASI75. Additionally, 55% of patients reported improvement in total body vitiligo, with 7% achieving T-VASI50.
• TEV-’408 was well-tolerated in the Phase 1b study, with no safety signals observed to date. The investigational antibody is designed for convenient quarterly (Q12W) subcutaneous dosing, which could offer a patient-friendly administration option. This favorable safety and dosing profile supports its continued development.
• The advancement of TEV-’408 into Phase 2b development aligns with Teva's "Pivot to Growth" strategy, prioritizing innovative, Teva-discovered immunology programs. Vitiligo is a chronic autoimmune disease with limited treatment options, especially for extensive disease, and TEV-’408 aims to address this significant unmet medical need by targeting the IL-15 pathway. The program is also supported by up to $500 million in strategic R&D funding from Royalty Pharma.

Addressing the Significant Unmet Needs in Vitiligo Treatment

Current vitiligo treatments face a confluence of efficacy, safety, accessibility, and mechanistic limitations that collectively underscore the substantial unmet need in this disease space. While a range of conventional modalities exists, none reliably deliver durable, disease-modifying repigmentation across the full patient population. The gap between available therapies and patient expectations continues to drive the search for more targeted and better-characterized treatment strategies.

• Limited specificity and modest efficacy of conventional therapies: Topical and oral corticosteroids, calcineurin inhibitors, and phototherapy lack immunological specificity, offer only modest repigmentation outcomes, and carry potential adverse effects with long-term use — making them inadequate as standalone, durable solutions.

• Absence of consistent long-term disease control: No existing therapy reliably achieves sustained remission for all patients, highlighting a critical unmet need for safe, effective treatments capable of controlling the disease over time.

• Accessibility barriers with phototherapy: Narrowband UVB (NB-UVB) phototherapy, despite its established use, requires frequent in-office visits — posing a meaningful accessibility challenge, particularly for patients with limited geographic or logistical access to dermatology centers.

• Inconsistent and adjunct-only value of systemic steroids: Oral minipulse steroids (OMP) demonstrated only adjunct value and were not sufficiently effective as monotherapy, limiting their standalone clinical utility.

• Conflicting efficacy data for emerging small molecule agents: Apremilast, a PDE4 inhibitor, showed variable outcomes — achieving up to 61.5% repigmentation in some cases but demonstrating only partial disease control and generally inferior efficacy compared to corticosteroids in halting disease progression.

• Therapeutic challenges in specific disease subtypes: Localized non-segmental vitiligo represents a particularly difficult-to-treat subtype, with existing modalities often falling short of clinically meaningful repigmentation thresholds.

• Incomplete understanding of pathogenesis limiting targeted innovation: A more nuanced characterization of vitiligo's underlying immunopathology is needed to identify precise therapeutic targets — underscored by the need for additional in vitro studies and large-scale clinical research to define which signaling pathways offer the most actionable intervention points.

• Unestablished long-term safety profile for newer agents: For JAK inhibitors and small molecule inhibitors, long-term safety data remain insufficient — particularly in pediatric and adolescent populations — and further studies are required to confirm efficacy, characterize safety, and assess the durability of repigmentation responses.

Teva's Anti-IL-15: A New Horizon for Vitiligo Treatment

Teva's decision to push its anti-IL-15 monoclonal antibody, TEV-’408, into Phase 2b for vitiligo signals a strategic move into a therapeutic area with significant unmet needs. Vitiligo, an autoimmune condition causing skin depigmentation, currently lacks highly effective, long-term systemic treatments. The scientific rationale for targeting interleukin-15 (IL-15) is compelling, as research shows this cytokine is a key orchestrator of immune responses, activating natural killer (NK) cells and driving inflammatory processes implicated in various autoimmune diseases, including arthritis and lupus. By neutralizing IL-15, TEV-’408 aims to dampen the autoimmune attack on melanocytes, potentially leading to repigmentation.

The early Phase 1b data is certainly encouraging, with a high percentage of patients experiencing facial repigmentation and a favorable safety profile. This suggests a promising clinical signal for the drug's novel mechanism of action. Furthermore, the proposed quarterly subcutaneous dosing regimen could be a significant differentiator, offering a level of convenience that may enhance patient adherence and market competitiveness in a chronic disease setting. This strategic advantage could position TEV-’408 favorably if efficacy is confirmed in larger trials.

However, several considerations warrant attention. The Phase 1b study was open-label, meaning larger, controlled trials are crucial to confirm these initial efficacy and safety signals without bias. Given IL-15's role in immune surveillance, particularly in augmenting NK cell activity and interferon-gamma production, there's a potential risk of immunosuppression or increased susceptibility to infections with long-term blockade. Future studies will need to carefully monitor these aspects. Ultimately, the success of TEV-’408 will hinge on demonstrating sustained repigmentation across various body areas and a robust safety profile in its upcoming Phase 2b and subsequent pivotal trials, potentially reshaping the treatment paradigm for vitiligo and validating IL-15 as a therapeutic target in broader autoimmune indications.